Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dialysis patients with hyperphosphataemia (≥ 1.94 mmol/L; ≥ 6.0 mg/dL)~* Stable dose of phosphate binder~* Written informed consent~Exclusion Criteria:~* Hyper/hypo calcemia; hyper intact parathyroid hormone (iPTH)~* Other significant medical conditions~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PA21 (2.5 g tablet) (Type: EXPERIMENTAL): None
- Sevelamer carbonate (Type: ACTIVE_COMPARATOR): None
- PA21-1 (1.25 g tablet) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).